Ochre Bio Bolsters Leadership Team and Board with Liver Disease Expertise to Advance Translational Research

Ochre Bio is thrilled to welcome two esteemed professionals to its team. David Coughlan, PhD has been appointed as Vice President of Translational Development, and Chinwe Ukomadu, MD, PhD has taken up a seat as an Observer on the Board of Directors. With their expertise and leadership, Ochre Bio is set to make strides in the development of chronic liver disease medicine.

Dr. David Coughlan, a pharmacist with over two decades of experience in pharmaceutical research and development, has been appointed to translate Ochre Bio’s groundbreaking discovery platform and human-based translational models into RNA therapies ready for clinical development. Most recently, he served as Chief Technical Officer of Afimmune Ltd. With his expertise, Dr. Coughlan is sure to make strides in the field of RNA therapy.

Dr Coughlan said:

I am thrilled to be joining the Ochre Bio team, where I am presented with the exciting opportunity to take part in ground-breaking science. With my experience in bringing novel scientific ideas to the clinic, I am eager to contribute to the mission of Ochre Bio and make a positive difference in the lives of those suffering from chronic liver disease.

Ochre’s revolutionary end-to-end RNA therapy development is bold and audacious: testing in live human donor livers to treat a wide variety of liver health and therapeutic challenges. It is an exciting prospect with the potential to revolutionize chronic disease treatment.

We are pleased to announce the appointment of David Wilkie to Ochre Bio’s Board of Directors, and the addition of Dr. Chinwe Ukomadu to the board as an observer. Dr. Ukomadu, an SVP and Head of GI Therapeutic Area at Takeda, brings a wealth of knowledge and expertise to the company, having served on the Ochre Bio Scientific Strategy Board previously.

With Dr. Ukomadu’s guidance, the leadership team is positioned to take early discoveries and transform them into a pipeline of therapeutics to improve patient outcomes.

Dr. Chinwe said:

I am truly humbled to have the opportunity to join the esteemed members of the Ochre Bio board. I am eager to collaborate with the SSB and the Board in order to aid Ochre Bio’s groundbreaking work and ultimately make a positive impact on the lives of patients.

Ochre Bio is revolutionizing the treatment of chronic liver disease with a groundbreaking foundation of transdisciplinary excellence and a team of world-class scientific minds. By embracing cutting-edge research, this company is paving the way for a brighter future of chronic liver disease care.

Quin Wills, CSO of Ochre Bio, commented:

We are thrilled to welcome David and Chinwe to our team, two experts who bring with them a wealth of world-class scientific and clinical expertise. As we embark on this crucial stage of our journey, it gives us immense pride to have such talented individuals join us.

With their extensive expertise in liver R&D and global drug development, we are confident that we can develop innovative treatments to improve the lives of those suffering from chronic liver disease. With their help, we are taking a big step forward in our mission to provide effective solutions for those in need.


Dr. David Coughlan is an accomplished professional with decades of expertise in directing, managing, and developing successful drug and clinical programs for multinational biotech and pharmaceutical companies from startup to market launch.

He started his career at Merrion Pharmaceuticals plc, where he held various senior technical and managerial positions in global development programs. He holds a B.Sc. in Pharmacy and PhD from Trinity College Dublin, Ireland, in addition to Postgraduate Diplomas in Quality Improvement and Financial Management. With a registered pharmacist status and multiple patents to his name, Dr. Coughlan has also written numerous research papers and abstracts in the pharmaceutical field.

Dr. Chinweike (Chinwe) Ukomadu is a highly accomplished physician-scientist with an impressive career trajectory. After earning his PhD and MD from Yale University and completing his residency and sub-specialty training in gastroenterology at Brigham and Women’s Hospital (BWH), he joined the staff of BWH and Harvard Medical School as an independent investigator, clinician and educator. After 21 years at BWH, Chinwe was recruited to Novartis Institutes

For Biomedical Research (NIBR), where he led the pre-clinical and translational strategy in gastroenterology and liver diseases. In 2021, Chinwe joined Takeda Pharmaceuticals as its Head of the GI Therapeutic Area Unit, where he is responsible for the gastroenterology pipeline and strategy in research and development.

Additionally, Dr. Ukomadu serves on the board of a number of biotech companies. With his wealth of knowledge and experience, Chinwe is a valuable asset to these organizations and the entire medical community.

About Ochre Bio

Ochre Bio is revolutionizing the treatment of chronic liver diseases with their cutting-edge RNA therapies. By leveraging deep phenotyping, precision RNA medicine, and testing in real human donor livers, they are actively developing breakthrough therapies to increase donor liver supply and reduce cirrhosis complications. Their revolutionary approach promises to revolutionize the way we care for and treat liver diseases.

Leave a Comment